Jyong Biotech (MENS) CEO Kuo reports 25,349,500-share indirect stake on Form 3

Rhea-AI Filing Summary

Jyong Biotech Ltd. CEO Fu-Feng Kuo filed an initial Form 3 reporting indirect beneficial ownership of 25,349,500 ordinary shares of the company. These shares are held through Perfect Minds Co., Ltd., which is ultimately owned via The Innovation Trust, where Ms. Kuo has authority over voting and investment decisions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider KUO FU-FENG

Role CEO

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 25,349,500 shares (Indirect, Held through Perfect Minds Co., Ltd, a Seychelles company.)

Footnotes (1)

1. [object Object]

Key Figures

Indirectly owned shares: 25,349,500 ordinary shares

1 metrics

Indirectly owned shares 25,349,500 ordinary shares Beneficially owned through Perfect Minds and The Innovation Trust

Key Terms

Form 3, beneficially own, discretionary trust, voting and dispositive power, +1 more

5 terms

Form 3 regulatory

"CEO Fu-Feng Kuo filed an initial Form 3 reporting indirect beneficial ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficially own financial

"Accordingly, Ms. Fu-Feng Kuo may be deemed to beneficially own 25,349,500 ordinary shares."

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

discretionary trust financial

"The Innovation Trust, a discretionary trust, (the "Trust")."

voting and dispositive power financial

"has sole voting and sole dispositive power over the 25,349,500 ordinary shares"

indirect ownership financial

"Held through Perfect Minds Co., Ltd, a Seychelles company."

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

KUO FU-FENG

(Last) (First) (Middle)

23F-3, NO.95, SEC. 1, XINTAI 5TH RD.

(Street)

NEW TAIPEI CITY TAIWAN, PROVINCE OF CHINA 221

(City) (State) (Zip)

TAIWAN

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/08/2026

3. Issuer Name and Ticker or Trading Symbol
Jyong Biotech Ltd. [ MENS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	25,349,500	I	Held through Perfect Minds Co., Ltd, a Seychelles company.(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 25,349,500 ordinary shares are held by Perfect Minds Co., Ltd., a Seychelles company ("Perfect Minds"), which is wholly owned by Innovation Global Group Limited, a British Virgin Islands company, which is wholly owned by The Innovation Trust, a discretionary trust, (the "Trust"). The Trust is managed by Unity Trust Limited, as the trustee. Ms. Fu-Feng Kuo is the Settlor, Appointor and one of the eligible beneficiaries of the Trust. Ms. Fu-Feng Kuo is also the sole director of Perfect Minds and has sole voting and sole dispositive power over the 25,349,500 ordinary shares by virtue of her authority to direct voting and investment decisions with respect to the securities held by Perfect Minds. Accordingly, Ms. Fu-Feng Kuo may be deemed to beneficially own 25,349,500 ordinary shares.

	Fu-Feng Kuo	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Jyong Biotech (MENS) CEO Fu-Feng Kuo report on this Form 3?

The Form 3 reports that CEO Fu-Feng Kuo beneficially owns 25,349,500 ordinary shares of Jyong Biotech Ltd. These are held indirectly through Perfect Minds Co., Ltd. and an associated trust structure where she controls voting and investment decisions.

How are the 25,349,500 Jyong Biotech (MENS) shares held by Fu-Feng Kuo structured?

The 25,349,500 ordinary shares are held by Perfect Minds Co., Ltd., wholly owned by Innovation Global Group Limited, which is wholly owned by The Innovation Trust. Ms. Kuo is settlor, appointor and a beneficiary, and she directs voting and investment decisions.

Does the Jyong Biotech (MENS) Form 3 show any recent insider buying or selling?

No transactions are reported; this Form 3 reflects existing holdings only. It lists 25,349,500 ordinary shares indirectly owned by CEO Fu-Feng Kuo through Perfect Minds Co., Ltd., without indicating any new purchases, sales, or option exercises.

Why is Fu-Feng Kuo considered a more than 10% owner of Jyong Biotech (MENS)?

Ms. Kuo may be deemed to beneficially own 25,349,500 ordinary shares, giving her more than 10% ownership. She holds sole voting and dispositive power over shares owned by Perfect Minds Co., Ltd. through her authority under the related trust structure.

What role does Perfect Minds Co., Ltd. play in Jyong Biotech (MENS) insider ownership?

Perfect Minds Co., Ltd., a Seychelles company, directly holds 25,349,500 ordinary shares of Jyong Biotech. CEO Fu-Feng Kuo is the sole director of Perfect Minds and controls voting and investment decisions, so she is treated as the beneficial owner of these shares.